Hemorrhagic shock in the pediatric trauma patient is an uncommon but fundamental
problem for the treating clinician. Current management of hemorrhagic shock involves initial …

In recent years the off-label use of recombinant activated factor VII (rFVIIa) has markedly
increased, particularly in pediatric cardiac surgery patients, and practitioners differ widely in …

One-third of patients with severe factor XI (FXI) deficiency caused by homozygosity for null
alleles develop inhibitor antibodies following exposure to plasma. Haemostasis during …

Severe FXI deficiency is a rare injury‐related bleeding disorder. In patients with FXI
inhibitors, surgeries may be treated using recombinant activated factor VII; however …

Objectives: Postoperative hemorrhage is a recognized complication of pediatric cardiac
surgery. Both the immature coagulation system and increased susceptibility to hemodilution …

Acute coagulopathy in pediatric trauma : Current Opinion in Pediatrics Acute coagulopathy
in pediatric trauma : Current Opinion in Pediatrics Log in or Register Subscribe to journalSubscribe …

Background Factor XI (FXI) deficiency is a rare autosomal bleeding disorder. The rarity of
spontaneous bleeding and absence of optimal tools to predict the bleeding risk in FXI …

Purpose Unlabeled uses of factor VIIa (recombinant) in pediatric patients are reviewed.
Summary Factor VIIa (recombinant) is currently approved for the treatment and prevention of …

Recombinant factor VIIa (rFVIIa)(NovoSeven; Novo Nordisk) was originally developed and
described by Hedner and Kisiel in 1983 for use in treating two patients presenting with …

Severe congenital Factor XI (FXI) deficiency (< 20% normal activity) can be associated with
significant bleeding disorders, and there has been great concern for severe bleeding …